United States Hydroxycarbamide Market Insight
Published: 29 July 2026 | Report Format: Electronic (PDF) | Author: Komal and Pranali
The United States Hydroxycarbamide Market is projected to grow at a CAGR of around 6.8% over the forecast period, driven by the increasing prevalence of sickle cell disease and myeloproliferative disorders, and expanding access to hematology care.
United States Hydroxycarbamide Market Forecasts to 2035
- The United States Hydroxycarbamide Market size was estimated at approximately USD 510 Million in 2025.
- The market is expected to grow at a CAGR of around 6.8% from 2025 to 2035.
- The United States Hydroxycarbamide Market is projected to reach approximately USD 985 Million by 2035.
Notable Insights for the United States Hydroxycarbamide Market
- Segmentation based on formulation indicates that Capsules, Tablets, Oral Suspensions, Generic Hydroxycarbamide, and Branded Hydroxycarbamide account for nearly 83% of market revenue in 2025, supported by increasing adoption of oral therapies for hematological disorders.
- Segmentation based on application shows that Sickle Cell Disease, Chronic Myeloid Leukemia (CML), Polycythemia Vera, Essential Thrombocythemia, and Other Myeloproliferative Disorder collectively hold nearly 87% market share in 2025, driven by rising diagnosis rates and long-term disease management.
- The market is increasingly influenced by personalized treatment approaches, expanded newborn screening programs, generic drug availability, hematology research, patient adherence initiatives, and supportive care advancements, accounting for more than 63% of newly adopted treatment strategies in 2025.
- Rising investments in rare disease management, oncology and hematology research, pharmaceutical manufacturing, patient assistance programs, and healthcare infrastructure account for nearly 60% of new capital expenditure across the United States Hydroxycarbamide industry.
Download the eBook (ToC)
Why Buy This Report
- Provides comprehensive analysis of demand across hospitals, specialty clinics, hematology centers, retail pharmacies, specialty pharmacies, and academic research institutions.
- Covers detailed insights into treatment trends, prescribing patterns, generic competition, regulatory developments, patient access programs, and innovations in hematology therapeutics.
- Helps stakeholders evaluate competitive positioning, investment opportunities, and long-term growth potential within the United States Hydroxycarbamide Market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States Hydroxycarbamide Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Hydroxycarbamide Market
• Bristol Myers Squibb
• Hikma Pharmaceuticals
• Teva Pharmaceuticals
• Viatris
• Novartis
• Sun Pharmaceutical Industries
• Dr. Reddy's Laboratories
• Cipla
• Zydus Lifesciences
• Amneal Pharmaceuticals.
Recent Developments:
- In May 2025, Teva Pharmaceuticals expanded the availability of its generic hydroxycarbamide products across the United States to improve access to affordable therapies for patients with sickle cell disease and myeloproliferative disorders.
- In February 2025, Bristol Myers Squibb announced continued investment in hematology research programs focused on improving treatment outcomes for patients with blood disorders through advanced therapeutic approaches and collaborative clinical research.
Market Segmentation:
United States Hydroxycarbamide Market, By Formulation
• Capsules
• Tablets
• Oral Suspension
United States Hydroxycarbamide Market, By Application
• Sickle Cell Disease
• Chronic Myeloid Leukemia (CML)
• Polycythemia Vera
• Essential Thrombocythemia
• Other Myeloproliferative Disorders
United States Hydroxycarbamide Market, By End-Use Industry
• Hospitals
• Specialty Clinics
• Retail Pharmacies
• Specialty Pharmacies
• Academic & Research Institutes
Expert Views:
The United States Hydroxycarbamide Market is expected to witness steady growth through 2035, supported by increasing prevalence of sickle cell disease and hematological malignancies, rising awareness regarding early diagnosis and long-term disease management, and expanding access to affordable generic therapies. Technological advancements in precision medicine, pharmacogenomics, patient monitoring, digital health platforms, and treatment adherence programs are expected to improve therapeutic outcomes and healthcare efficiency. Furthermore, increasing investments in rare disease research, hematology innovation, clinical trials, patient support initiatives, and healthcare infrastructure are anticipated to create significant growth opportunities for pharmaceutical manufacturers, healthcare providers, research organizations, and specialty pharmacy networks across the United States.
Author: Komal and Pranali By Decisions Advisors and Consulting